Alopecia areata has affected roughly 7 million Americans without a single FDA-approved systemic treatment — until now. Baricitinib works by blocking the inflammatory signals that cause the immune system to attack hair follicles, giving them a chance to recover. In clinical trials, one in three patients with severe cases regrew enough hair to cover at least 80% of their scalp. Approval also unlocks insurance coverage, turning a once-inaccessible therapy into a realistic option. This breakthrough shows how a single curious clinician, one patient, and a decade of persistence can rewrite what medicine believes is possible.